Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Amgen’s Prolia/Xgeva (denosumab) could have another use in a rare bone disease, according to a small NIH-funded Phase II study, adding to its approvals in other bone disorders as biosimilar competition is on its way.
The monoclonal antibody “significantly reduced abnormal bone turnover in adults” with the rare disease, known as fibrous dysplasia, according to the results of the eight-person study, carried out by the National Institute of Dental and Craniofacial Research (NIDCR) and the NIH Clinical Center. Bone turnover, which occurs when old bone is replaced with new bone, is unusually accelerated in those with fibrous dysplasia and contributes to bone abnormalities, NIH said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.